These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27051119)

  • 21. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe stomatitis complicating treatment with pegylated-interferon alpha-2a and ribavirin in an HCV-infected patient.
    Borrás-Blasco J; Primo J; Rosique-Robles JD; Casterá E; Abad FJ; Jiménez I
    South Med J; 2008 Jan; 101(1):88-90. PubMed ID: 18176299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
    Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N
    Ann Hepatol; 2008; 7(1):87-90. PubMed ID: 18376374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Cooksley WG; Piratvisuth T; Lee SD; Mahachai V; Chao YC; Tanwandee T; Chutaputti A; Chang WY; Zahm FE; Pluck N
    J Viral Hepat; 2003 Jul; 10(4):298-305. PubMed ID: 12823597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C.
    Moriya K; Yasuda K; Koike K; Ichinose Y; Yotsuyanagi H; Kurokawa K; Iino S
    J Gastroenterol; 1994 Aug; 29(4):514-7. PubMed ID: 7951865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.
    Ji F; Li Z; Xue H; Liu L; Deng H
    South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
    Arora A; Vargas L; Kuzniar TJ
    J Hosp Med; 2009 Sep; 4(7):E45-6. PubMed ID: 19753589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy.
    Ichikawa-Yamada Y; Joshita S; Tsukahara Y; Kimura T; Morita S; Kamijo A; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Tanaka E
    Hepatol Res; 2011 Sep; 41(9):904-9. PubMed ID: 21884341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.
    Bosques-Padilla F; Trejo-Estrada R; Campollo-Rivas O; Cortez-Hernández C; Dehesa-Violante M; Maldonado-Garza H; Pérez-Gómez R; Cabrera-Valdespino A
    Ann Hepatol; 2003; 2(3):135-9. PubMed ID: 15115965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
    Rasenack J; Zeuzem S; Feinman SV; Heathcote EJ; Manns M; Yoshida EM; Swain MG; Gane E; Diago M; Revicki DA; Lin A; Wintfeld N; Green J
    Pharmacoeconomics; 2003; 21(5):341-9. PubMed ID: 12627987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
    N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK; Lai LS; Lam P; Zhang HY; Fung TT; Lai ST; Wong WM; Lo CM; Fan ST; Leung N; Lau GK;
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1171-8. PubMed ID: 16611278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
    Liu CH; Liang CC; Lin JW; Chen SI; Tsai HB; Chang CS; Hung PH; Kao JH; Liu CJ; Lai MY; Chen JH; Chen PJ; Kao JH; Chen DS
    Gut; 2008 Apr; 57(4):525-30. PubMed ID: 17881538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.